WFIPP welcomes our new Corporate Partner Amara Therapeutics. Amara Therapeutics is an Irish-based Digital Therapeutics company who develop app-based treatments for patients suffering from Overactive Bladder (OAB). The company is a spin out from the University of Galway in Ireland and their mission is to make clinically proven, guideline recommended, behavioural therapy available to all […]Read more
Some interested articles/interviews and podcast in the latest newsletter of EAU Edu Platform on Functional Urology (UROLUTS)Read more
Antimicrobial Resistance: A Spotlight on Urinary Tract Infections – Is there an issue?
In recent years, there has been a notable increase in antimicrobial resistance and multi-drug resistance among community-acquired uropathogens, predominantly Escherichia coli and Klebsiella pneumoniae, causing urinary tract infections (UTI). The availability of effective oral treatments limited by antimicrobial resistance is of growing concern.
This workshop is aiming at HCP’s.
The Clinical Leadership workshop will have engaging, interactive discourse with experts on topics ranging from physician-patient communication, patient engagement to actively identifying patient needs and gaining a better understanding of the benefits and value of patient engagement and why this is important.
What will you do if you encounter challenging patient cases with unfavourable outcomes? How will you execute clear communication and relay realistic outcome predictions to patients? The Plenary Session: Incontinence nightmares will provide you with vital information on the importance of counselling and patient information when offering surgical treatments. This session will offer expert insights through eye-opening case presentations […]Read more
After receiving such a variety of high-quality abstract submissions, the 38th Annual EAU Congress in Milan is shaping up to be the largest platform for sharing breaking urology research and innovations in 2023! From the 4,570 abstracts submitted for presentation, 1,304 have been accepted, as well as 127 video abstracts, which makes a total acceptance rate of 31.3%. You can now view the full list of selected abstracts that […]Read more
On the 7th of December 2022 WFIPP took part as one of the partners in the ‘P’-Word Project for a first ever session at the European Parliament in Brussels, hosted by MEP Tomislav SOKOL. The focus of the meeting was how to deal with incontinence issues, not only in relation to prostate and bladder cancer, but […]Read more
The World Federation of Incontinence and Pelvic Problems (WFIPP), has given Minze Health the opportunity to conduct a short survey among its patients via the WFIPP websites, its member organizations and other healthcare professionals within its network. One of the main questions in the survey is to ask whether patients would pay out of pocket […]Read more
Adult incontinence products are a bigger waste problem than nappies, according to researchers. (ABC News: Jon Kerr) Adult incontinence products outnumber baby nappies in landfill — and could outstrip them 10-to-one by 2030, according to a new Australian study. Key points: Experts want policy change to divert adult incontinence products from landfill They say these products are a bigger […]Read more
Evidence of PFAS in sanitary and incontinence pads The findings come on the heels of other testing that found the forever chemicals in some popular tampons. EHN Staff December 02, 2022 Twenty-two sanitary pads, panty liners and incontinence pads have detectable levels of fluorine, an indicator of the group of chemicals known as PFAS, […]Read more
Following the consultation with our members, EPF has finalised its official position statement on the EHDS proposal. The statement, together with the amendments, will guide our advocacy strategy and will shape our interactions with the co-legislators. Our key recommendations put the patients at the very heart of this initiative. Trust, transparency, meaningful involvement of patients and their representatives, […]Read more
Some interesting articles in this month’s newsletter, The Public Edition, from Bowel & Bowel UKRead more
On 15th November 2022 the EU Health Coalition has published a vision for European health, supported by a set of concrete recommendations and policy proposals designed to make it happen. The Coalition is a multi-stakeholderinitiative exploring the future of healthcare in Europe. Its new vision will be launched today in Brussels at the 3rdEU Health […]Read more
Healthcare is undergoing a major transformation, and technology will transform how we receive or deliver healthcare. The Dynamic Coalition on Digital Health, Internet Governance Forum, United Nations, is preparing the “Digital Health” report for 2022, for which we are conducting primary research via a survey. We would like to have your valuable input on it. It would be great if […]Read more
The PIONEER Big Data Platform offers a central and federated state-of-the-art Big Data analytic platform for prostate cancer. The platforms anonymous data is harmonised to the European Common Data Model, OMOP-CDM, following all legal and ethical requirements. The PIONEER Big Data platform brings together diverse datasets, contributed by our Partners and Associated Members, including the […]Read more
In the SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy), researchers at the University of Zurich are currently investigating a novel treatment option. This is a so-called “Phase II study”, which is designed to assess the efficacy and safety of the new treatment option.
MUVON THERAPEUTICS IS URGENTLY LOOKING FOR PATIENTS WHO ARE WILLING TO TAKE PART IN THIS TRIAL IN SWITZERLAND.